Techcyte, Inc.

Techcyte, Inc. is a US-based company specializing in digital pathology solutions that enhance laboratory workflows and improve diagnostic accuracy through advanced AI technology. Techcyte, Inc. focuses on providing digital pathology services, consolidating clinical and anatomic pathology into one platform.

Founded in 2014 in Orem, US by Ralph Yarro, the company has completed three deals with a notable funding round in December 2023, raising USD 8. 4 mn. Ben Cahoon serves as CEO. Techcyte offers a comprehensive digital pathology platform that integrates clinical and anatomic pathology into a singular solution, enhancing laboratory workflows and facilitating improved diagnostic processes.

Central to their offerings is the Techcyte Fusion™, an advanced AI-powered platform designed to assist pathologists by optimizing image acquisition and analysis, streamlining reporting, and ensuring compliance with industry standards such as FDA, CE, and HIPAA. The platform serves a diverse clientele, including laboratories in the realms of anatomic pathology, clinical pathology, veterinary medicine, and environmental testing. Techcyte's solutions are geared towards enhancing the efficiency and accuracy of diagnostic procedures, with products tailored to specific applications in surgical pathology, cytology, microbiology, hematology, and more. The company's offerings are primarily available in the United States for research use, while also being CE-IVDD marked for distribution in European markets.

Techcyte's revenue model is predominantly based on subscriptions and strategic partnerships within the healthcare sector, targeting laboratories and diagnostic centers. Clients typically engage with Techcyte through annual or multi-year subscription agreements that provide access to their flagship products, including the Fusion AP and various specialized suites like the Fusion Bacteriology Suite and Techcyte SureView™ Cervical Cytology System. This structure allows clients to leverage cutting-edge AI technology without the burden of significant upfront investments. The pricing structure reflects the comprehensive nature of the services, with different tiers designed to accommodate varying laboratory needs and sizes.

Through these transactions, Techcyte fosters long-term relationships with healthcare providers, ensuring ongoing support and updates to maintain compliance with evolving regulatory standards. In December 2023, Techcyte, Inc. raised USD 8. 4 mn in venture funding, which will be allocated towards the development of new products and expansion into new markets.

The company is focusing on launching additional features for the Techcyte Fusion™ platform, aimed at improving diagnostic capabilities. Expansion plans include targeting laboratories in Europe and Asia by 2025, leveraging this funding to enhance their market presence and operational capabilities.